Tailoring Treatment Approaches in Psoriasis Management - Episode 10
Applying Learnings From the SPECTREM Study to Clinical Practice
Panelists discuss how the SPECTREM study (Stein Gold, 2024) demonstrated guselkumab’s remarkable efficacy for moderate psoriasis in high-impact areas, with 74% of treated patients achieving clear/almost clear skin (Investigator’s Global Assessment [IGA] 0/1) at week 16 compared with just 12% on placebo, while importantly showing consistent effectiveness regardless of baseline body surface area (BSA)—suggesting that BSA alone shouldn’t determine treatment approach and validating biologic therapy for patients with limited but highly impactful disease.
Video content above is prompted by the following:
- What were some of the key findings of the SPECTREM study? (Stein Gold, 2024)
- 74% of patients on guselkumab achieved the primary end point of IGA 0/1 at week 16 compared with placebo (12%).
Over 70% of patients were able to achieve the primary end point regardless of baseline BSA.
